uMR 680

The uMR 680 is a 1.5T superconducting magnetic resonance diagnostic system designed to acquire high-quality anatomical, functional, and spectroscopic images of the head, body, and extremities for diagnostic support, potentially utilizing contrast agents. It integrates advanced hardware, such as high-channel RF coils and a 70cm bore, with innovative software including AI-powered image enhancement (DeepRecon), noise reduction (QScan), automated workflow tools (EasyScan), and specialized cardiac and organ-specific spectroscopy applications.

The uMR 680 is a 1.5 Tesla superconducting magnetic resonance diagnostic device (MRDD) featuring a 70cm patient bore. It is designed to produce sagittal, transverse, coronal, and oblique cross-sectional images, as well as spectroscopic images, to display internal anatomical structure and/or function of the head, body, and extremities. These images and derived physical parameters, when interpreted by a trained physician, provide information that may assist in diagnosis, and contrast agents may be used depending on the scan's region of interest. The system comprises components such as a magnet, RF and gradient power amplifiers, RF and gradient coils, a patient table, spectrometer, computer, and various support systems, and conforms to NEMA and DICOM standards. The uMR 680 incorporates several technological advancements. Hardware enhancements include an increased number of receive channels (up to 96), a suite of new and modified RF coils (e.g., Head & Neck Coil-24, Spine Coil-32, Body Array Coil-24, Flex Coils-8, SuperFlex coils, and an Infant Coil-24 for pediatric exams), and an optional dockable patient table with a higher load capacity. Key software innovations include 'DeepRecon,' a deep-learning algorithm for image de-noising and K-space interpolation-based super-resolution, trained on over 165,000 cases and tested on diverse US subjects, showing improved SNR and resolution. Other new software features are 'QScan' for reduced acoustic noise, 'EasyScan' for automated slice positioning, 'Flow Quantification (FQ)', 'Inline T2 Mapping', 'Cardiac T1, T2, and T2* Mapping', specialized spectroscopy sequences for the liver, prostate, and breast, and an MR conditional implant mode for enhanced safety.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the 'DeepRecon' algorithm handle images with significant motion artifacts or those acquired with very low signal-to-noise ratios, and what is its impact on the visibility of subtle pathological features compared to standard reconstruction methods?; What are the specific gradient waveform optimization strategies employed by 'QScan,' and how do these affect parameters like echo time (TE), repetition time (TR), and specific absorption rate (SAR) in noise-reduced sequences?; What is the underlying technology or methodology of the 'EasyScan' automatic slice positioning, and how does its accuracy and consistency compare across different body regions (e.g., head vs. abdomen) and patient demographics?; Regarding the cardiac mapping functionalities (T1, T2, T2*), what is the validation process for their accuracy and precision, and how do these values correlate with histological findings or established non-invasive cardiac biomarkers?; For the specialized spectroscopy sequences (Liver, Prostate, Breast), what are the quantifiable improvements in metabolite detection and quantification, and how does this enhanced capability translate to improved diagnostic confidence or earlier disease detection in clinical practice?